title: Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases.
abstract: OBJECTIVE
  Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence.
  
  
  RESULTS
  Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative.
  
  
  CONCLUSIONS
  This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.
authors.affiliation: Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: Thaer
authors.initials: T
authors.lastname: Khoury
authors.forename: Rouzan G
authors.initials: RG
authors.lastname: Karabakhtsian
authors.forename: David
authors.initials: D
authors.lastname: Mattson
authors.forename: Li
authors.initials: L
authors.lastname: Yan
authors.forename: Susanna
authors.initials: S
authors.lastname: Syriac
authors.forename: Fadi
authors.initials: F
authors.lastname: Habib
authors.forename: Song
authors.initials: S
authors.lastname: Liu
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Desouki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012306:Risk
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: adjuvant therapy; breast; local recurrence; pleomorphic lobular carcinoma in situ